Holen Sie sich die Stockscreener-App
5.775
10.51%
-0.695
Handel nachbörslich:
5.78
0.005
+0.09%
Schlusskurs vom Vortag:
$6.47
Offen:
$6.35
24-Stunden-Volumen:
1.88M
Relative Volume:
2.42
Marktkapitalisierung:
$317.02M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-3.4172
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
+2.84%
1M Leistung:
+20.88%
6M Leistung:
+11.99%
1J Leistung:
-3.50%
1-Tages-Spanne:
$5.59
$6.36
1-Wochen-Bereich:
$5.59
$6.64
52-Wochen-Spanne:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.775 | 355.17M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics secures $130M loan facility to advance clinical pipeline - ca.proactiveinvestors.com
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc - MarketScreener
Candel Therapeutics Secures $130M Loan for Trials - TipRanks
Candel Therapeutics secures $130M loan to advance cancer therapy trials - Proactive financial news
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - The AI Journal
Candel Therapeutics secures $130 million term loan facility - Investing.com
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - The Manila Times
Candel Therapeutics Incannounces encouraging interim data from CAN-3110 trial - MarketScreener
Candel Therapeutics Reports Promising Interim Data for CAN-3110 in Recurrent Glioblastoma and Publication in Science Translational Medicine - Quiver Quantitative
Candel Therapeutics Announces Positive Interim Data After - GlobeNewswire
Candel Therapeutics Reports CAN-3110 Pathologic CR, mOS 12.0 mo | CADL Stock News - Stock Titan
Can Candel Therapeutics Inc. stock sustain revenue growthMarket Sentiment Summary & Daily Chart Pattern Signal Reports - newser.com
Candel Therapeutics Inc. stock retracement – recovery analysisEntry Point & High Accuracy Swing Trade Signals - newser.com
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer - Stocktwits
What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in
Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com
Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com
Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How resilient is Candel Therapeutics Inc. stock in market downturns2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times
Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative
Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan
Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial - Proactive financial news
Tanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADL - MarketBeat
H.C. Wainwright reiterates Buy rating on Candel Therapeutics stock at $23 price target - Investing.com Australia
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛
HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating | CADL Stock News - GuruFocus
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):